Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss

NCT01451853 is registered in ClinicalTrials.gov with Sound Pharmaceuticals, Incorporated as lead sponsor.

NCT NCT01451853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01451853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss
Lead sponsor
Sound Pharmaceuticals, Incorporated
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2026
Completion date
June 30, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, hearing loss, lung cancer, neuropathy, ototoxicity, tinnitus